Telix Pharmaceuticals Limited (TLX)
Automate Your Wheel Strategy on TLX
With Tiblio's Option Bot, you can configure your own wheel strategy including TLX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TLX
- Rev/Share 3.5211
- Book/Share 1.2513
- PB 11.9831
- Debt/Equity 0.9913
- CurrentRatio 1.333
- ROIC 0.063
- MktCap 5075375480.7025
- FreeCF/Share 0.0176
- PFCF 857.2587
- PE 145.4731
- Debt/Assets 0.3515
- DivYield 0
- ROE 0.0702
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TLX | Citigroup | -- | Buy | -- | $22 | Sept. 18, 2025 |
| Downgrade | TLX | JP Morgan | Overweight | Neutral | -- | -- | Aug. 28, 2025 |
| Initiation | TLX | H.C. Wainwright | -- | Buy | -- | $23 | July 3, 2025 |
| Initiation | TLX | Wedbush | -- | Outperform | -- | $22 | June 5, 2025 |
News
ATTENTION NASDAQ: TLX INVESTORS: Contact Berger Montague About a Telix Pharmaceuticals Ltd. Class Action Lawsuit
Published: December 02, 2025 by: PRNewsWire
Sentiment: Neutral
PHILADELPHIA , Dec. 2, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period").
Read More
Telix Pharmaceuticals (TLX) Faces Securities Class Action After Alleged Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman
Published: December 01, 2025 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO , Dec. 1, 2025 /PRNewswire/ -- Telix Pharmaceuticals Ltd. (NASDAQ: TLX), a commercial-stage biopharmaceutical company specializing in diagnostic and therapeutic radiopharmaceuticals, is now the target of a securities class action lawsuit following a series of regulatory setbacks and steep stock declines over the summer.
Read More
TLX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Telix Pharmaceuticals Limited Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: December 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Telix Pharmaceuticals Limited (“Telix” or “the Company”) (NASDAQ: TLX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Telix securities between February 21, 2025 and August 28, 2025, both dates inclusive (the “Class Period”).
Read More
Bragar Eagel & Squire, P.C. Reminds Investors of Telix Pharmaceuticals and Firefly Aerospace to Contact the Firm About their Rights Before Lead Plaintiff Deadlines
Published: November 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Telix Pharmaceuticals Limited (NASDAQ:TLX) and Firefly Aerospace Inc. (NASDAQ:FLY). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Read More
ROSEN, THE FIRST FILING FIRM, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – TLX
Published: November 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 28, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the “Class Period”), of the important January 9, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.
Read More
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals
Published: November 28, 2025 by: Newsfile Corp
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Telix To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Telix between February 21, 2025 and August 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - November 28, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Telix Pharmaceuticals Limited ("Telix" …
Read More
Telix Pharmaceuticals Ltd. Shareholders with Large Losses Should Contact Robbins LLP for Information About the TLX Class Action
Published: November 28, 2025 by: PRNewsWire
Sentiment: Neutral
SAN DIEGO , Nov. 28, 2025 /PRNewswire/ -- Company: Telix Pharmaceuticals Ltd. (NASDAQ: TLX) is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies.
Read More
TLX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Telix Pharmaceuticals Limited Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: November 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Telix Pharmaceuticals Limited (“Telix” or “the Company”) (NASDAQ: TLX) and certain of its officers.
Read More
Telix Pharmaceuticals Limited (TLX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: November 26, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Nov. 26, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Telix Pharmaceuticals Limited ("Telix" or the "Company") (NASDAQ: TLX). IF YOU SUFFERED A LOSS ON YOUR TELIX INVESTMENTS, CLICK HERE BEFORE JANUARY 9, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?
Read More
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals
Published: November 26, 2025 by: Newsfile Corp
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Telix To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Telix between February 21, 2025 and August 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - November 26, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Telix Pharmaceuticals Limited ("Telix" …
Read More
Telix Pharmaceuticals (TLX) Hit with Investor Lawsuit Alleging Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman
Published: November 26, 2025 by: PRNewsWire
Sentiment: Neutral
TLX Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO , Nov. 26, 2025 /PRNewswire/ -- Telix Pharmaceuticals Ltd. (NASDAQ: TLX), a commercial-stage biopharmaceutical company specializing in diagnostic and therapeutic radiopharmaceuticals, is now the target of a securities class action lawsuit following a series of regulatory setbacks and steep stock declines over the summer.
Read More
Telix Pharmaceuticals Limited (TLX) Faces Securities Class Action Amid SEC Subpoena, Complete Response Letter -- Hagens Berman
Published: November 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (NASDAQ: TLX), a commercial-stage biopharmaceutical company focused on medical imaging and therapeutic radiopharmaceuticals, is now the target of a securities class action lawsuit, capping a tumultuous several months that saw the company's stock crater following revelations of a regulatory subpoena and an FDA rejection letter. National shareholders rights firm Hagens Berman is actively investigating the alleged legal claims and urges Telix investors who suffered substantial losses to submit your losses now.
Read More
Investors in Telix Pharmaceuticals Ltd. Should Contact The Gross Law Firm Before January 9, 2026 to Discuss Your Rights – TLX
Published: November 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX).
Read More
Telix Pharmaceuticals Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – TLX
Published: November 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 24, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against Telix Pharmaceuticals Limited (“Telix” or “the Company”) (NASDAQ: TLX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of TLX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
Read More
Telix Pharmaceuticals Limited (TLX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: November 24, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Nov. 24, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Telix Pharmaceuticals Limited ("Telix" or the "Company") (NASDAQ: TLX) have opportunity to lead the securities fraud class action lawsuit.
Read More
TLX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Telix Pharmaceuticals Limited Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: November 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Telix Pharmaceuticals Limited (“Telix” or “the Company”) (NASDAQ: TLX) and certain of its officers.
Read More
Telix Pharmaceuticals Limited (TLX) Faces Securities Class Action Amid SEC Subpoena, Complete Response Letter -- Hagens Berman
Published: November 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (NASDAQ: TLX), a commercial-stage biopharmaceutical company focused on medical imaging and therapeutic radiopharmaceuticals, is now the target of a securities class action lawsuit, capping a tumultuous several months that saw the company's stock crater following revelations of a regulatory subpoena and an FDA rejection letter.
Read More
TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Limited Securities Fraud Lawsuit with the Schall Law Firm
Published: November 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 21, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Telix Pharmaceuticals Limited (“Telix” or “the Company”) (NASDAQ: TLX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 21, 2025 and August 28, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before January 9, 2026.
Read More
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals
Published: November 21, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Telix To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Telix between February 21, 2025 and August 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Nov. 21, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Telix Pharmaceuticals Limited ("Telix" or the …
Read More
Telix Pharmaceuticals Limited (TLX) Faces Securities Class Action Amid SEC Subpoena, Complete Response Letter -- Hagens Berman
Published: November 20, 2025 by: Newsfile Corp
Sentiment: Neutral
TLX Investors with Losses Encouraged to Contact the Firm San Francisco, California--(Newsfile Corp. - November 20, 2025) - Telix Pharmaceuticals Limited (NASDAQ: TLX), a commercial-stage biopharmaceutical company focused on medical imaging and therapeutic radiopharmaceuticals, is now the target of a securities class action lawsuit, capping a tumultuous several months that saw the company's stock crater following revelations of a regulatory subpoena and an FDA rejection letter. National shareholders rights firm Hagens Berman is actively investigating the alleged legal claims and urges Telix investors who suffered substantial losses to submit your losses now.
Read More
TLX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Telix Pharmaceuticals Limited Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: November 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Telix Pharmaceuticals Limited (“Telix” or “the Company”) (NASDAQ: TLX) and certain of its officers.
Read More
ZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal Masses
Published: November 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
MELBOURNE, Australia and INDIANAPOLIS, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces results from the ZIRCON-X study which finds that almost half of all patients imaged with TLX250-CDx (Zircaix®1, 89Zr-DFO-girentuximab) PET/CT2 would have undergone a change in clinical management, when compared with baseline standard of care (SOC) imaging. The data will be presented at the 26th Annual Meeting of the Society of Urologic Oncology (SUO) being held in Phoenix, AZ, December 2 – 5, 2025.
Read More
Berger Montague PC Investigating Claims on Behalf of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) After Class Action Filing
Published: November 19, 2025 by: PRNewsWire
Sentiment: Neutral
PHILADELPHIA , Nov. 19, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix" or the "Company") on behalf of investors who purchased Telix securities during the period of February 21, 2025 through August 28, 2025 (the "Class Period").
Read More
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TLX
Published: November 18, 2025 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - November 18, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025 and August 28, 2025, both dates inclusive (the "Class Period").
Read More
Telix Pharmaceuticals Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - TLX
Published: November 18, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Nov. 18, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Telix Pharmaceuticals Limited ("Telix" or "the Company") (NASDAQ: TLX ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of TLX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
Read More
Deadline Alert: Telix Pharmaceuticals Limited (TLX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: November 18, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP reminds investors of the upcoming January 9, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX) securities between February 21, 2025 and August 28, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR TELIX INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING C.
Read More
Telix Pharmaceuticals Limited (TLX) Faces Securities Class Action Amid SEC Subpoena, Complete Response Letter -- Hagens Berman
Published: November 18, 2025 by: PRNewsWire
Sentiment: Neutral
TLX Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO , Nov. 18, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (NASDAQ: TLX), a commercial-stage biopharmaceutical company focused on medical imaging and therapeutic radiopharmaceuticals, is now the target of a securities class action lawsuit, capping a tumultuous several months that saw the company's stock crater following revelations of a regulatory subpoena and an FDA rejection letter. National shareholders rights firm Hagens Berman is actively investigating the alleged legal claims and urges Telix investors who suffered substantial losses to submit your losses now.
Read More
Class Action Lawsuit Filed Against Telix Pharmaceuticals Ltd. (TLX) - Recover Losses - Contact Levi & Korsinsky Before January 9, 2026
Published: November 18, 2025 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - November 18, 2025) - If you suffered a loss on your Telix Pharmaceuticals Ltd. (NASDAQ: TLX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/telix-pharmaceuticals-ltd-lawsuit-submission-form?prid=177942&wire=5&utm_campaign=9 or contact Joseph E.
Read More
Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately
Published: November 18, 2025 by: PRNewsWire
Sentiment: Neutral
Lead Plaintiff Deadline is January 9, 2026 NEW YORK , Nov. 18, 2025 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP reminds purchasers or acquirers of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix) American Depositary Shares ("ADS") between February 21, 2025 and August 28, 2025 (the "Class Period") have until January 9, 2026 to seek appointment as lead plaintiff.
Read More
Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately
Published: November 18, 2025 by: PRNewsWire
Sentiment: Neutral
Lead Plaintiff Deadline is January 9, 2026 NEW YORK , Nov. 18, 2025 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP reminds purchasers or acquirers of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) ("Telix") American Depositary Shares ("ADS") between February 21, 2025 and August 28, 2025 (the "Class Period") have until January 9, 2026 to seek appointment as lead plaintiff.
Read More
About Telix Pharmaceuticals Limited (TLX)
- IPO Date 2024-11-14
- Website https://telixpharma.com
- Industry Biotechnology
- CEO Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD,
- Employees None